Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Single-Round Infectious Particle Antiviral Screening Assays for the Japanese Encephalitis Virus.

Lu CY, Hour MJ, Wang CY, Huang SH, Mu WX, Chang YC, Lin CW.

Viruses. 2017 Apr 10;9(4). pii: E76. doi: 10.3390/v9040076.

2.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.

Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64. doi: 10.1128/AAC.00051-16. Print 2016 May.

3.

The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry.

Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, Lloyd AR, Beard MR.

J Biol Chem. 2015 Oct 23;290(43):25946-59. doi: 10.1074/jbc.M115.657346. Epub 2015 Sep 9.

4.

Viruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinoma.

Hibner U, Grégoire D.

Contemp Oncol (Pozn). 2015;19(1A):A62-7. doi: 10.5114/wo.2014.47132. Review.

5.

Unfolded protein response in hepatitis C virus infection.

Chan SW.

Front Microbiol. 2014 May 20;5:233. doi: 10.3389/fmicb.2014.00233. eCollection 2014. Review.

6.

NS2 proteins of GB virus B and hepatitis C virus share common protease activities and membrane topologies.

Boukadida C, Marnata C, Montserret R, Cohen L, Blumen B, Gouttenoire J, Moradpour D, Penin F, Martin A.

J Virol. 2014 Jul;88(13):7426-44. doi: 10.1128/JVI.00656-14. Epub 2014 Apr 16.

7.

Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems.

Kato N, Sejima H, Ueda Y, Mori K, Satoh S, Dansako H, Ikeda M.

PLoS One. 2014 Mar 13;9(3):e91156. doi: 10.1371/journal.pone.0091156. eCollection 2014.

8.

Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee.

Yi M, Hu F, Joyce M, Saxena V, Welsch C, Chavez D, Guerra B, Yamane D, Veselenak R, Pyles R, Walker CM, Tyrrell L, Bourne N, Lanford RE, Lemon SM.

J Virol. 2014 Apr;88(7):3678-94. doi: 10.1128/JVI.03540-13. Epub 2014 Jan 15.

9.

Isolation and characterization of highly replicable hepatitis C virus genotype 1a strain HCV-RMT.

Arai M, Tokunaga Y, Takagi A, Tobita Y, Hirata Y, Ishida Y, Tateno C, Kohara M.

PLoS One. 2013 Dec 16;8(12):e82527. doi: 10.1371/journal.pone.0082527. eCollection 2013.

10.

Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.

Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, You S, Remlinger K, Duan M, Kazmierski W, Hamatake R.

Antimicrob Agents Chemother. 2014;58(1):38-47. doi: 10.1128/AAC.01363-13. Epub 2013 Oct 14.

11.
12.

Raloxifene inhibits hepatitis C virus infection and replication.

Takeda M, Ikeda M, Mori K, Yano M, Ariumi Y, Dansako H, Wakita T, Kato N.

FEBS Open Bio. 2012 Aug 22;2:279-83. doi: 10.1016/j.fob.2012.08.003. Print 2012.

13.

Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis.

Simonin Y, Vegna S, Akkari L, Grégoire D, Antoine E, Piette J, Floc'h N, Lassus P, Yu GY, Rosenberg AR, Karin M, Durantel D, Hibner U.

PLoS Pathog. 2013 Mar;9(3):e1003234. doi: 10.1371/journal.ppat.1003234. Epub 2013 Mar 21.

14.

Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry.

Kim S, Ishida H, Yamane D, Yi M, Swinney DC, Foung S, Lemon SM.

J Virol. 2013 Apr;87(8):4214-24. doi: 10.1128/JVI.00954-12. Epub 2013 Jan 30.

15.

Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.

Huang H, Kang R, Wang J, Luo G, Yang W, Zhao Z.

Autophagy. 2013 Feb 1;9(2):175-95. doi: 10.4161/auto.22791. Epub 2012 Nov 20.

16.

Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.

Xu S, Pei R, Guo M, Han Q, Lai J, Wang Y, Wu C, Zhou Y, Lu M, Chen X.

J Virol. 2012 Dec;86(23):13025-37. doi: 10.1128/JVI.01785-12. Epub 2012 Sep 26.

17.

Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay.

Yu X, Sainz B Jr, Petukhov PA, Uprichard SL.

Antimicrob Agents Chemother. 2012 Dec;56(12):6109-20. doi: 10.1128/AAC.01413-12. Epub 2012 Sep 4.

18.

Comparison of Helicobacter bilis-Associated Protein Expression in Huh7 Cells Harbouring HCV Replicon and in Replicon-Cured Cells.

Okoli AS, Raftery MJ, Mendz GL.

Int J Hepatol. 2012;2012:501671. doi: 10.1155/2012/501671. Epub 2012 Jul 30.

19.

New hepatitis C virus drug discovery strategies and model systems.

Hussain S, Barretto N, Uprichard SL.

Expert Opin Drug Discov. 2012 Sep;7(9):849-59. doi: 10.1517/17460441.2012.711312. Epub 2012 Aug 4. Review.

20.

A twist in the tail: SHAPE mapping of long-range interactions and structural rearrangements of RNA elements involved in HCV replication.

Tuplin A, Struthers M, Simmonds P, Evans DJ.

Nucleic Acids Res. 2012 Aug;40(14):6908-21. doi: 10.1093/nar/gks370. Epub 2012 May 4.

Supplemental Content

Support Center